In 2023, Complete Omics secured investment from world-leading venture capital firms, accelerating the scale-up of our clinical proteomics platforms and advancing the measurement infrastructure for next-generation diagnostics and precision medicine.
World-Leading Venture Capital Backs the Scaling of Our Clinical Proteomics Platforms
In 2023, Complete Omics secured investment from leading global venture capital firms to accelerate the development and scaling of its clinical proteomics platforms. The investment marked a major milestone in the company’s journey, providing the resources needed to expand its technologies from advanced research tools into scalable platforms capable of supporting large-scale clinical and pharmaceutical applications.
The funding round was led by world-class venture investors including Qiming Venture Partners, one of the most respected life science investment firms globally. Known for backing many of the most successful biotechnology companies, the firm recognized the transformative potential of Complete Omics’ technologies in building the measurement infrastructure for the human proteome.
Scaling the Next Generation of Clinical Proteomics
The investment supports the expansion of Complete Omics’ core technology platforms, including:
- Complete360®, an ultra-deep clinical proteomics platform designed to measure thousands of proteins across complex clinical samples
- Valid-NEO®, a targeted neoantigen validation platform enabling direct detection and quantification of mutation-derived peptides
- CompleteCohort™, a large-scale multi-omics analysis framework designed to support cohort-scale clinical studies
Together, these platforms enable researchers and clinicians to systematically measure molecular signals across human diseases, supporting applications ranging from early disease detection and biomarker discovery to therapeutic target identification and drug development.
From Scientific Innovation to Scalable Infrastructure
Since its founding, Complete Omics has pursued a long-term vision: transforming proteomics from a specialized research capability into a scalable molecular measurement platform for precision medicine.
The support from leading venture investors enables the company to expand its technological infrastructure, including:
- advanced mass spectrometry instrumentation
- optimized protein enrichment and sample preparation workflows
- large-scale peptide reference libraries
- computational systems for high-throughput proteomics analysis
These investments are designed to support the next phase of the company’s growth—scaling its technologies to support large clinical cohorts, pharmaceutical partnerships, and real-world medical applications.
Building the Proteomic Layer of Precision Medicine
The global healthcare system increasingly relies on molecular measurements to guide diagnostics and treatment decisions. While genomic sequencing has become widely accessible, the ability to systematically measure proteins across clinical samples remains a major technological frontier.
Complete Omics is working to address this challenge by building the measurement infrastructure necessary to make the human proteome accessible at scale.
The 2023 investment therefore represents more than financial support—it reflects growing recognition that clinical proteomics will play a central role in the future of precision medicine.
With the backing of leading venture capital investors, Complete Omics is continuing to expand its platforms and partnerships to accelerate the translation of proteomics technologies into real-world clinical impact.
At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr.